40 Organometallics, Vol. 24, No. 1, 2005
Yu et al.
Diphenyl(1-benzyl-3-methyl-2-indolyl)phosphine
(P(C6H5)2(C16H14N), (N-Bz)-1). The preparation for (N-Me)-1
was followed. (N-Bz)-1 was obtained as a white powder (0.20
g, 52%). Crystals suitable for single-crystal X-ray diffraction
were obtained from slow evaporation of the ligand in a
hexane-dichloromethane solution. Anal. Calcd for C22H20NP
(405.2): C, 82.94; H, 5.97; N, 3.45. Found: C, 83.04; H, 6.04;
N, 3.45. 31P{1H} NMR (CDCl3, δ, ppm): -32.0. 1H NMR (CDCl3,
δ, ppm): 6.83-7.62 (m, 19H), 5.61 (d, 2H, 4JPH ) 3 Hz, CH2-
N), and 2.26 (s, 3H, CH3 on indole). 13C{1H} NMR (CDCl3, δ,
ppm): 138.8, 137.8, 134.8, 132.3, 129.1, 129.0, 128.5, 128.4,
128.3, 128.2, 126.3, 126.1, 123.3, 121.9, 119.3, 110.3, 48.4, and
10.7. EI-MS: m/z 405 [M+, 100], 328 [M+ - Ph, 8], and 314
[M+ - CH2C6H5, 24].
Diphenyl[1-(2,3,4,5,6-pentafluorobenzyl)-3-methyl-2-
indolyl]phosphine (P(C6H5)2(C16H9F5N), (N-F5Bz)-1). The
preparation for (N-Me)-1 was followed. (N-F5Bz)-1 was
obtained as a white powder (0.26 g, 56%). HRMS (EI) for
C28H19F5NP (M+): calcd, 495.1175; found, 495.1182. 31P{1H}
NMR (CDCl3, δ, ppm): -30.8 (t, 6JPFo ) 25 Hz). 19F{1H} NMR
Phenylbis[1-(2,3,4,5,6-pentafluorobenzyl)-3-methyl-2-
indolyl]phosphine (P(C6H5)(C16H9F5N)2, (N-F5Bz)2-2). The
preparation for (N-Me)2-2 was followed. (N-F5Bz)2-2 was
obtained as a white powder (0.19 g, 32%). HRMS (EI) for
C38H23F10N2P (M+): calcd, 728.1439; found, 728.1428. 31P{1H}
NMR (CDCl3, δ, ppm): -52.3 (quintet, 6JPFo ) 20 Hz). 19F{1H}
NMR (CDCl3, δ, ppm): -142.3 (ddd, 6JPFo ) 28 Hz, 3JFoFm(cis)
)
22 Hz, 5JFoFm(trans) ) 8 Hz, 4F, o-F), -154.6 (t, 3JFpFm ) 21 Hz,
3
3
2F, p-F), and -162.3 (ddd, JFmFo(cis) ) 22 Hz, JFmFp) 21 Hz,
5JFmFo(trans) ) 8 Hz, 4F, m-F). 1H NMR (CDCl3, δ, ppm): 7.17-
2
7.54 (m, 13H), 5.75 (d, 2H, JHH ) 17 Hz, N-CH2), 5.65 (d,
2
2H, JHH ) 17 Hz, N-CH2), and 1.82 (s, 6H, CH3 on indole).
13C{1H} NMR (CDCl3, δ, ppm): 146.2, 143.8, 141.4, 139.5,
138.2, 135.8, 132.6, 131.4, 128.9, 128.8, 128.5, 125.1, 123.7,
122.3, 119.7, 118.9, 111.0, 109.0, 37.1, and 9.3. EI-MS: m/z
728 [M+, 100], 547 [M+ - CH2C6F5, 8], and 181 [CH2C6F5
21].
,
+
Phenylbis(1-(R)-(-)-myrtenyl-3-methyl-2-indolyl)phos-
phine (P(C6H5)(C19H22N)2, (N-(R)-(-)myrtenyl)2-2). The
preparation for (N-Me)2-2 was followed. (N-(R)-(-)myrte-
nyl)2-2 was obtained as a white powder (0.21 g, 40%). HRMS
(EI) for C44H29N2P (M+): calcd, 636.3633; found, 636.3641. 31P-
{1H} NMR (CDCl3, δ, ppm): -55.2. 1H NMR (CDCl3, δ, ppm):
6.89-7.47 (m, 13H), 4.87 (d, 2H, 2JHH ) 17 Hz, N-CH2), 4.75
6
3
(CDCl3, δ, ppm): -141.6 (ddd, JPFo ) 31 Hz, JFoFm(cis) ) 23
Hz, 5JFoFm(trans) ) 8 Hz, 2F, o-F), -154.2 (t, 3JFpFm ) 21 Hz, 1F,
3
3
p-F), and -161.1 (ddd, JFmFo(cis) ) 23 Hz, JFmFp) 21 Hz,
5JFmFo(trans) ) 8 Hz, 2F, m-F). 1H NMR (CDCl3, δ, ppm): 7.13-
7.53 (m, 14H), 5.75 (s, 2H, CH2-N), and 2.80 (s, 3H, CH3 on
indole). 13C{1H} NMR (CDCl3, δ, ppm): 146.6, 143.9, 141.7,
139.2, 138.7, 138.5, 136.0, 134.2, 132.3, 129.2, 129.1, 128.5,
128.4, 123.6, 122.4, 119.5, 111.6, 109.2, 37.6, and 10.4. EI-
2
(d, 2H, JHH ) 17 Hz, N-CH2), 4.66 (s, 2H, alkene CH on
myrtenyl), 2.37 (m, 2H, CH on myrtenyl), 2.24 (s, 4H, CH2
bridge on myrtenyl), 2.19 (s, 2H, CH on myrtenyl), 1.84 (s, 6H,
CH3 on indole), 0.99 (s, 6H, CH3 on myrtenyl), 0.90 (d, 4H,
3JHH ) 7 Hz, CH2 on myrtenyl), and 0.59 (s, 6H, CH3 on
myrtenyl). 13C{1H} NMR (CDCl3, δ, ppm): 144.3, 138.9, 135.8,
132.9, 130.0, 129.0, 128.6, 128.3, 123.3, 122.7, 118.9, 118.8,
117.8, 110.3, 49.1, 43.4, 40.4, 38.1, 31.4, 30.8, 26.1, 20.9, and
MS: m/z 495 [M+, 100], 418 [M+ - Ph, 54], 314 [M+
-
CH2C6F5, 20], and 181 [CH2C6F5+, 28].
Diphenyl(1-(R)-(-)-myrtenyl-3-methyl-2-indolyl)phos-
phine (P(C6H5)2(C19H22N), (N-(R)-(-)-myrtenyl)-1). The
preparation for (N-Me)-1 was followed. (N-(R)-(-)-myrte-
nyl)-1 was obtained as a white powder (0.18 g, 42%). HRMS
(EI) for C31H32NP (M+): calcd, 449.2272. found, 449.2278. 31P-
{1H} NMR (CDCl3, δ, ppm): -31.9. 1H NMR (CDCl3, δ, ppm):
6.96-7.58 (m, 14H), 5.01 (d, 1H, 2JHH ) 17 Hz, N-CH2), 4.89
10.1. EI-MS: m/z 636 [M+, 44], 621 [M+ - Me, 18], 559 [M+
-
Ph, 6], 501 [M+ - myrtenyl, 23], and 264 [1-myrtenyl-3-
methylindole, 25].
Bis(1-methyl-3-indolyl)methane-(2,12)-phenylphos-
phine (P(C6H5)(C19H16N2), (N-Me)2-3). The preparation for
(N-Me)-1 was followed, with the exception of using P(C6H5)-
(C17H12N2) (3; 0.30 g, 0.85 mmol), NaH (0.049 g, 1.18 mmol),
and iodomethane (0.12 mL, 1.93 mmol). (N-Me)2-3 was
obtained as a white powder (0.27 g, 82%). Crystals suitable
for X-ray diffraction were obtained by slow evaporation of the
ligand from a hexane-dichloromethane solution. HRMS (EI)
for C25H21N2P (M+): calcd, 380.1442; found, 380.1437. 31P{1H}
NMR (CDCl3, δ, ppm): -64.4. 1H NMR (CDCl3, δ, ppm): 7.17-
2
(d, 1H, JHH ) 17 Hz, N-CH2), 4.51 (s, 1H, alkene CH on
myrtenyl), 2.31 (s, 2H, CH2 bridge on myrtenyl), 2.26 (s, 1H,
CH on myrtenyl), 2.20 (m, 1H, CH on myrtenyl), 1.88 (s, 3H,
CH3 on indole), 1.14 (s, 3H, CH3 on myrtenyl), 0.96 (d, 2H,
3JHH ) 6 Hz, CH2 on myrtenyl), and 0.70 (s, 3H, CH3 on
myrtenyl). 13C{1H} NMR (CDCl3, δ, ppm): 144.4, 138.6, 135.3,
132.6, 132.4, 128.8, 128.4, 128.3, 128.1, 122.8, 119.0, 117.0,
110.4, 109.4, 49.0, 43.5, 40.8, 38.2, 31.4, 30.8, 26.1, 21.0, and
10.6. EI-MS: m/z 449 [M+, 100] and 434 [M+ - Me, 15].
Phenylbis(1,3-dimethyl-2-indolyl)phosphine (P(C6H5)-
(C10H10N)2, (N-Me)2-2). The preparation for (N-Me)-1 was
followed, with the exception of using P(C6H5)(C9H8N)2 (2; 0.30
g, 0.82 mmol), NaH (0.047 g, 1.96 mmol), and iodomethane
(0.11 mL, 1.77 mmol). (N-Me)2-2 was obtained as a white
product (0.15 g, 38%). HRMS (EI) for C26H25N2P (M+): calcd,
396.1755; found, 396.1752. 31P{1H} NMR (CDCl3, δ, ppm):
-53.3. 1H NMR (CDCl3, δ, ppm): 7.10-7.56 (m, 13H), 3.65 (s,
6H, CH3-N), and 2.04 (s, 6H, CH3 on indole). 13C{1H} NMR
(CDCl3, δ, ppm): 139.3, 134.2, 132.5, 130.9, 128.8, 128.7, 128.4,
126.7, 122.9, 120.6, 119.0, 109.1, 123.3, 31.5, and 9.9. EI-MS:
m/z 396 [M+, 100], 381 [M+ - CH3, 6], 252 [M+ - (1,3-
methylindole), 13], and 144 [(1,3-methylindole)+, 17].
2
4
7.79 (m, 13H), 4.64 (dd, 1H, JHH ) 21 Hz, JPH ) 4 Hz, CH2
bridge), 4.48 (dd, 1H, 2JHH ) 21 Hz, 4JPH ) 4 Hz, CH2 bridge),
and 3.72 (s, 6H, CH3 on indole). 13C{1H} NMR (CDCl3, δ,
ppm): 139.6, 136.1, 134.3, 130.0, 129.8, 128.8, 127.1, 122.4,
119.1, 118.8, 115.7, 109.0, 31.0, and 21.5. EI-MS: m/z 380 [M+,
100], 365 [M+ - Me, 8], 303 [M+ - Ph, 31].
Bis(1-benzyl-3-indolyl)methane-(2,12)-phenylphos-
phine (P(C6H5)(C31H24N2), (N-Bz)2-3). The preparation for
(N-Me)2-3 was followed. (N-Bz)2-3 was obtained as a white
powder (0.38 g, 84%). HRMS (EI) for C37H29N2P (M+): calcd,
532.2068; found, 532.2070. 31P{1H} NMR (CDCl3, δ, ppm):
-66.3. 1H NMR (CDCl3, δ, ppm): 6.78-7.84 (m, 23H), 5.50
2
2
(d, 2H, JHH ) 17 Hz, N-CH2), 5.35 (d, 2H, JHH ) 17 Hz,
N-CH2), 4.74 (dd, 1H, 2JHH ) 21 Hz, 4JPH ) 3 Hz, CH2 bridge),
2
4
and 4.60 (dd, 1H, JHH ) 21 Hz, JPH ) 3 Hz, CH2 bridge).
13C{1H} NMR (CDCl3, δ, ppm): 142.7, 139.3, 137.4, 134.3,
130.3, 128.5, 128.4, 127.7, 127.0, 126.2, 122.7, 119.5, 118.9,
Phenylbis(1-benzyl-3-methyl-2-indolyl)phosphine
(P(C6H5)(C16H14N)2). The preparation for (N-Me)2-2 was
followed. (N-Bz)2-2 was obtained as a white powder (0.19 g,
46%). HRMS (EI) for C38H33N2P (M+): calcd, 548.2381; found,
548.2370. 31P{1H} NMR (CDCl3, δ, ppm): -53.6. 1H NMR
116.3, 110.0, 48.4, and 22.7. EI-MS: m/z 532 [M+, 89], 455
[M+ - Ph, 8], 441 [M+ - CH2C6H5, 81], and 91 [CH2C6H5
,
+
2
100].
(CDCl3, δ, ppm): 6.65-7.46 (m, 23H), 5.37 (d, 2H, JHH ) 17
Hz, N-CH2), 5.28 (d, 2H, 2JHH ) 17 Hz, N-CH2), and 1.89 (s,
6H, CH3 on indole). 13C{1H} NMR (CDCl3, δ, ppm): 138.8,
137.9, 133.0, 132.6, 129.3, 128.6, 128.4, 128.1, 126.7, 126.5,
126.0, 123.0, 121.1, 119.1, 118.9, 109.9, 48.1, and 10.1. EI-
MS: m/z 548 [M+, 9], 457 [M+ - Benz, 7], 220 [1-benzyl-3-
methylindole+, 8] and 91 [benzyl+, 100].
Bis[1-(2,3,4,5,6-pentafluorobenzyl)-3-indolyl]methane-
(2,12)-phenylphosphine (P(C6H5)(C31H14F10N2), (N-F5Bz)2-
3). The preparation for (N-Me)2-3 was followed. (N-F5Bz)2-3
was obtained as a white powder (0.56 g, 92%). Crystals suitable
for single-crystal X-ray diffraction were obtained from slow
evaporation of the ligand in a CDCl3 solution. HRMS (EI) for